Filtered By:
Condition: Atrial Fibrillation
Procedure: Anesthesia

This page shows you your search results in order of date.

Order by Relevance | Date

Total 276 results found since Jan 2013.

The Price of Keeping the Rhythm: Increased Bleeding Risk in Patients with Atrial Fibrillation Concurrently Prescribed Amiodarone and Factor Xa Inhibitors
Atrial fibrillation is the most common sustained cardiac arrhythmia affecting nearly 2% of the population of the United States.1 Patients with atrial fibrillation are twice as likely to have a myocardial infarction and five-times as likely to have a stroke.1 Current guidelines recommend antiarrhythmic pharmacotherapy in patients with symptomatic atrial fibrillation as first-line management.2-4 Amiodarone is a very effective, and therefore, a commonly prescribed agent for this purpose.5 Anticoagulation is a key tenet in the management of atrial fibrillation due to the increased tendency of left atrial appendage clot formati...
Source: Journal of Cardiothoracic and Vascular Anesthesia - August 10, 2023 Category: Anesthesiology Authors: Nicolas Kumar, Manoj H. Iyer, Adam Dalia, Amit Bardia Tags: Editorial Source Type: research

E-248 Rescue intracranial stenting for failed posterior circulation thrombectomy: analysis from saint study
ConclusionIn patients with posterior circulation occlusion stokes who failed mechanical thrombectomy, our study suggests that RS has better outcomes with comparable safety profile. Randomized controlled studies are warranted for more concrete evidence.Abstract E-248 Table 1Baseline demographic, clinical and procedural characteristics among rescue stenting and failed reperfusion groups Rescue stentingN=84 Failed ReperfusionN=68 P value Age 63.6±12.6 69.7±13.5 0.005 Female 18 (21.4%) 35 (51.5%) <0.001 Ethnic BackgroundWhiteAAHispanicAsianOthers 33 (39.3%)20 (23.8%)22 (26.2%)4 (4.8%)5 (6%) 34 (50%)22 (32.4%)...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Mohammaden, M., Tarek, M., Haussen, D., Fifi, J., Matsoukas, S., Farooqui, M., Ortega-Gutierrez, S., Zevallos, C., Galecio-Castillo, M., Hassan, A., Tekle, W., Al-Bayati, A., Salem, M., Burkhardt, J., Pukenas, B., Cortez, G., Hanel, R., Aghaebrahim, A., S Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

PerIoperative iNflammatory reSponse assessment In hiGH-risk patienTs undergoing non-cardiac surgery (INSIGHT): study protocol of a prospective non-interventional observational study
This study was approved by the ethics committees at the Medical University of Vienna (2458/2020) and at the Medical University of Graz (33-274 ex 20/21). Trial registration number NCT04753307.
Source: BMJ Open - July 19, 2023 Category: General Medicine Authors: Pichler, A., Kurz, A., Eichlseder, M., Graf, A., Eichinger, M., Taschner, A., Kabon, B., Fleischmann, E., Reiterer, C., for the INSIGHT study group, Pichler, Reiterer, Eichlseder, Graf, Eichinger, Kabon, Hantakova, Schallmeiner, Kuhrn, Kurz, Taschner, Fre Tags: Open access, Anaesthesia Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Predictors of Symptomatic Intracranial Hemorrhage after Endovascular Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Conclusions: This study identified many predictors of sICH. Some of the results lack robust evidence given the limitations of the study. Therefore, larger cohort studies are needed to confirm these predictors.Cerebrovasc Dis
Source: Cerebrovascular Diseases - November 24, 2022 Category: Neurology Source Type: research

Increased blood pressure variability during general anaesthesia is associated with worse outcomes after mechanical thrombectomy: a prospective observational cohort study
Conclusions Increased intraprocedural BPV was more likely to have poor functional outcome in patients with LVO following MT with general anaesthesia. This finding indicates that special precautions should be taken to minimise BP fluctuation during procedure.
Source: BMJ Open - October 5, 2022 Category: General Medicine Authors: Xu, C., Jin, T., Chen, Z., Zhang, Z., Zhang, K., Mao, H., Ye, S., Geng, Y., Shi, Z. Tags: Open access, Neurology Source Type: research

Anesthetic management using remimazolam in a patient with atrial flutter: a case report
Am J Transl Res. 2022 Aug 15;14(8):5754-5759. eCollection 2022.ABSTRACTRemimazolam is a new intravenously administered ultra-short-acting benzodiazepine used in anesthesia or sedation. Remimazolam offers several advantages over other short-acting sedatives, including an organ-independent metabolism and rapid and predictable onset and recovery. Furthermore, remimazolam shows less cardiovascular-inhibitory effects than other anesthetics. Atrial flutter is a form of cardiac arrhythmia that is associated with serious health-related outcomes and a substantial economic burden. Acute onset of atrial flutter can cause cardiac dysf...
Source: American Journal of Translational Research - September 15, 2022 Category: Research Authors: Joo Yong Lee Hyeon Tae Kim Yae Jee Kim Jin Sol Lee Jin Wook Park Young Duck Shin Source Type: research